12

Psychedelic biotech startup Psylo raises $5 million Seed round

 2 years ago
source link: https://www.startupdaily.net/topic/funding/psychedelic-biotech-startup-psylo-raises-5-million-seed-round/
Go to the source link to view the article. You can view the picture content, updated content and better typesetting reading experience. If the link is broken, please click the button below to view the snapshot at that time.
neoserver,ios ssh client

News » Topics » Funding » Psychedelic biotech startup Psylo raises $5 million Seed round

Funding

Psychedelic biotech startup Psylo raises $5 million Seed round

Simon Thomsen - October 27, 2022 < 1 MIN READ

Psylo-Josh-Sam.jpeg
Pyslo counders Joshua Ismin and Samuel Banister
Psylo, a preclinical biotech firm, has raised $5 million in Seed funding as it looks to treat mental illness with naturally occurring psychedelic drugs.

The fresh capital comes 12 months after the Sydney-based startup emerged Startmate‘s winter 21 cohort with an initial $1.1 million in capital from the likes Airtree’s Daniel Petre in a round led led by Chris Hitchen’s global micro-VC fund Possible Ventures. 

Psylo more recently took part in the UNSW Founders SynBio 10x accelerator program and set up shop at the university.

Last year the former Australian federal government launched a $15 million fund for psychedelic clinical trials, and in July 2021, the Psychae Institute, a $40 million psychedelic research centre, opened in Melbourne. 

Psylo is focused on  psychedelic-assisted therapy using psilocybin, the active molecule in ‘magic mushrooms’, is increasingly being evaluated as a potential treatment for severe mental illness. The biotech startup hopes to initially develop a shorter-acting version of psilocybin, which normally takes effect for 6-8 hours in duration.

Ongoing research suggests psilocybin is significantly more effective in treating major depression that existing options, and the startup is seizing its opportunity at a time where the pharmaceutical industryls investment in clinical research programs for mental illness has fallen by 70% in the last decade. 

The CSIRO’s deep tech VC arm Main Sequence Ventures led the new round supported by US investor Lionheart Ventures, psychedelics-focused VCs Negev Capital and Empath Ventures, and New Zealand healthcare fund CaraMed Capital.

The startup’s Chief Scientific Officer, Samuel Banister, is formerly team leader in medicinal chemistry at the Brain and Mind Centre at the University of Sydney.

The new cash will be used to expand the team of researchers as the company looks to ramp up its clinical R&D.


report

Recommend

About Joyk


Aggregate valuable and interesting links.
Joyk means Joy of geeK